CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
一箭双靶：淋巴瘤与 HIV 的潜在联合治疗方案
英文原题：One arrow for two targets: potential co-treatment regimens for lymphoma and HIV.
查看英文原题
One arrow for two targets: potential co-treatment regimens for lymphoma and HIV.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2007年，一名感染HIV的患者（“柏林患者”）因急性髓系白血病接受了两次异基因造血干细胞移植（allo-HSCT），供者携带HIV共受体CCR5的纯合突变（CCR5Δ32）；治疗白血病的同时，也清除了患者体内HIV。十年后，“伦敦患者”也取得类似成功。这两例病例提示，来自合适供者的allo-HSCT可用于治疗血液系统恶性肿瘤并控制HIV。此外，其他新型抗淋巴瘤疗法也能有效抑制HIV复制，包括CAR-T 细胞免疫疗法、PD-1／程序性死亡配体1（PD-L1）阻断，以及靶向肿瘤关键分子通路的疗法。本综述讨论这些方法在淋巴瘤治疗和抗HIV治疗中的应用。
展开英文摘要原文
In 2007, an HIV-infected individual (Berlin patient) underwent two allogeneic haematopoietic stem cell transplantations (allo-HSCTs) from a donor with a homozygous mutation in the HIV co-receptor CCR5 (CCR5 32) for the treatment of acute myeloid leukaemia, which eradicated HIV from infected patients simultaneously. Ten years later, another success in the 'London patient' was reported. These two cases suggest that allo-HSCT from a suitable donor is feasible for the treatment of haematological malignancies and HIV.
Moreover, other novel approaches for anti-lymphoma have effectively suppressed HIV replication, including chimeric antigen receptor T-cell (CAR-T) immunotherapy, PD-1/Programmed death-ligand-1 (PD-L1) blockade, and therapies based on mechanisms that target the critical molecular pathways of tumour. This review discusses these approaches for both lymphoma and anti-HIV therapy.
论文信息
- 作者
- Chen X、Jia L、Zhang X、Zhang T、Zhang Y
- 第一作者单位
- Department of Infectious Diseases, Beijing You An Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing Key Laboratory for HIV/AIDS Research, Beijing 100069, China.China
- 通讯作者单位
- Department of Infectious Diseases, Beijing You An Hospital, Capital Medical University, Beijing Institute of Hepatology, Beijing Key Laboratory for HIV/AIDS Research, Beijing 100069, China. Electronic address: yulinzhang@ccmu.edu.cn.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Blood reviews2022 Sep
- 原文标识
- PubMed 35489964 · DOI 10.1016/j.blre.2022.100965